Citation & Authors
Front Immunol. 2026;17:1768882.
ABSTRACT · CHINESE TRANSLATION
Translated abstract
Translated from the licensed abstract via the Chinese version. This is not an official journal translation.
purpose
To investigate the association between metformin use and incident immune-mediated diseases (IMDs) in patients with type 2 diabetes.
method
This retrospective cohort study used the National Health Insurance Research Database to include patients newly diagnosed with type 2 diabetes during 2000–2017 and followed them through the end of 2018. Users were defined as receiving metformin for ≥28 days. Baseline characteristics were balanced by 1:1 propensity score matching. The primary outcome was incident IMD; secondary outcomes were IMD-related hospitalization and all-cause mortality. Dose–response analyses categorized cumulative exposure as <182 days, 182–364 days, or >364 days. Cox models estimated HRs and 95% confidence intervals.
result
After matching, each group included 20,460 patients. Metformin was associated with higher risks of incident IMD (adjusted HR 2.36; 95% CI 2.09–2.67) and IMD-related hospitalization (2.44; 1.94–3.05), but lower all-cause mortality (0.64; 0.60–0.68). With increasing cumulative exposure, risks of IMD and related hospitalization increased progressively, while all-cause mortality decreased.
Conclusion
In patients with type 2 diabetes, metformin use was associated with higher risks of incident IMD and related hospitalization but lower all-cause mortality. This highlights its dual immunometabolic associations and the need for individualized monitoring and further mechanistic research.
Original work: Author of the above paper. Source:Public Summary ↗. This translation is based on the Chinese rendering of the original English abstract.
Original work license:CC BY ↗;Translations are subject to the same licensing conditions.
